Towa Pharmaceutical Co., Ltd. (FRA:6QC)

Market Cap	978.30M +23.4%
Revenue (ttm)	1.49B +5.4%
Net Income	28.64M -72.3%
EPS	0.58 -72.4%
Shares Out	n/a
PE Ratio	34.16
Forward PE	n/a
Dividend	0.45 (2.19%)
Ex-Dividend Date	Mar 30, 2026

Volume	n/a
Open	19.70
Previous Close	19.60
Day's Range	19.70 - 19.70
52-Week Range	15.20 - 23.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About Towa Pharmaceutical

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, Injectable, Patches, eye drops, and other products. It also offers IT service related to healthcare; disease risk testing services; and quasi drugs. In ...

• Industry: Pharmaceutical Preparations
• Founded: 1951
• Employees: 4,788
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6QC

Financial Performance

In fiscal year 2026, Towa Pharmaceutical's revenue was 273.71 billion, an increase of 5.44% compared to the previous year's 259.59 billion. Earnings were 5.25 billion, a decrease of -72.35%.

Financial numbers in JPY